GSK plc (LON:GSK – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Friday . The stock traded as low as GBX 13.92 ($0.18) and last traded at GBX 1,391.20 ($17.54), with a volume of 1314462 shares. The stock had previously closed at GBX 1,388.80 ($17.51).
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on GSK shares. JPMorgan Chase & Co. reduced their price target on GSK from GBX 1,400 ($17.65) to GBX 1,300 ($16.39) in a research report on Tuesday, August 1st. Bank of America reduced their price target on GSK from GBX 1,450 ($18.28) to GBX 1,390 ($17.52) in a research report on Monday, July 17th. Shore Capital reaffirmed a “buy” rating on shares of GSK in a research note on Friday, June 16th. Jefferies Financial Group reaffirmed a “hold” rating and set a GBX 1,575 ($19.85) price objective on shares of GSK in a research note on Monday, June 26th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a GBX 1,700 ($21.43) price objective on shares of GSK in a research note on Thursday, June 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, GSK has a consensus rating of “Hold” and a consensus price target of GBX 1,560 ($19.66).
GSK Price Performance
GSK Announces Dividend
The company also recently declared a dividend, which will be paid on Thursday, October 12th. Shareholders of record on Thursday, August 17th will be paid a GBX 14 ($0.18) dividend. This represents a dividend yield of 1.01%. The ex-dividend date of this dividend is Thursday, August 17th. GSK’s dividend payout ratio is 4,409.45%.
Insider Buying and Selling at GSK
In related news, insider Jonathan Symonds acquired 6,000 shares of the firm’s stock in a transaction dated Friday, June 23rd. The stock was bought at an average price of GBX 1,440 ($18.15) per share, for a total transaction of £86,400 ($108,912.14). In related news, insider Jonathan Symonds acquired 6,000 shares of the firm’s stock in a transaction dated Friday, June 23rd. The stock was bought at an average price of GBX 1,440 ($18.15) per share, for a total transaction of £86,400 ($108,912.14). Also, insider Hal Barron sold 19,446 shares of the firm’s stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of GBX 3,462 ($43.64), for a total value of £673,220.52 ($848,632.95). Insiders have bought 6,027 shares of company stock valued at $8,676,567 in the last 90 days. 1.74% of the stock is currently owned by company insiders.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Five stocks we like better than GSK
- How to Invest in Esports
- MarketBeat Week in Review – 8/28 – 9/1
- How to Buy Cheap Stocks Step by Step
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- How to Invest in Blue Chip Stocks
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.